Accelerate Current Deferred Revenue vs Other Stockholder Equity Analysis

AXDX Stock

USD 0.88 0.04 4.35%

Accelerate Diagnostics financial indicator trend analysis is way more than just evaluating Accelerate Diagnostics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Accelerate Diagnostics is a good investment. Please check the relationship between Accelerate Diagnostics Current Deferred Revenue and its Other Stockholder Equity accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Accelerate Diagnostics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.

For more information on how to buy Accelerate Stock please use our How to Invest in Accelerate Diagnostics guide.

Current Deferred Revenue vs Other Stockholder Equity

Current Deferred Revenue vs Other Stockholder Equity Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Accelerate Diagnostics Current Deferred Revenue account and Other Stockholder Equity. At this time, the significance of the direction appears to have strong relationship.

The correlation between Accelerate Diagnostics' Current Deferred Revenue and Other Stockholder Equity is 0.73. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Other Stockholder Equity in the same time period over historical financial statements of Accelerate Diagnostics, assuming nothing else is changed. The correlation between historical values of Accelerate Diagnostics' Current Deferred Revenue and Other Stockholder Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of Accelerate Diagnostics are associated (or correlated) with its Other Stockholder Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Stockholder Equity has no effect on the direction of Current Deferred Revenue i.e., Accelerate Diagnostics' Current Deferred Revenue and Other Stockholder Equity go up and down completely randomly.

Correlation Coefficient

0.73

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Other Stockholder Equity

Most indicators from Accelerate Diagnostics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Accelerate Diagnostics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Accelerate Diagnostics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.

For more information on how to buy Accelerate Stock please use our How to Invest in Accelerate Diagnostics guide.At this time, Accelerate Diagnostics' Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 219.4 K in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 3.8 M in 2024.

	2023	2024 (projected)
Interest Income	1.3M	1.2M
Non Recurring	2.7K	2.4K

Interest Income Non Recurring

Accelerate Diagnostics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock Total Equity	Common Stock	Current Deferred Revenue	Other Liab	Other Assets	Treasury Stock
Total Assets		0.77	0.04	0.43	0.7	0.08	-0.21	0.14	0.76	0.54	0.02	0.98	0.25	0.14	0.52	-0.17	0.32	0.51	0.25	1.0	-0.58	-0.57	-0.1	-0.68	0.04	-0.32
Other Current Liab	0.77		0.24	-0.11	0.84	0.57	-0.7	0.42	0.38	0.79	-0.3	0.65	0.72	0.53	0.75	0.35	0.74	0.78	0.69	0.74	-0.55	-0.52	0.33	-0.5	0.23	-0.77
Total Current Liabilities	0.04	0.24		-0.27	0.37	0.25	-0.54	0.6	0.04	0.37	-0.04	-0.03	0.43	0.28	0.02	0.31	0.53	0.29	0.3	0.02	-0.26	-0.25	0.23	0.35	0.11	-0.47
Total Stockholder Equity	0.43	-0.11	-0.27		-0.24	-0.82	0.55	-0.18	0.47	-0.41	0.59	0.55	-0.51	-0.25	-0.5	-0.52	-0.37	-0.55	-0.4	0.47	-0.12	-0.12	-0.25	-0.23	-0.59	0.66
Property Plant And Equipment Net	0.7	0.84	0.37	-0.24		0.59	-0.66	0.38	0.46	0.94	-0.29	0.6	0.65	0.35	0.81	0.2	0.65	0.88	0.58	0.66	-0.61	-0.6	0.1	-0.48	0.45	-0.77
Net Debt	0.08	0.57	0.25	-0.82	0.59		-0.66	0.14	-0.3	0.7	-0.7	-0.06	0.69	0.28	0.81	0.4	0.52	0.84	0.5	0.03	-0.13	-0.14	0.23	-0.26	0.64	-0.83
Retained Earnings	-0.21	-0.7	-0.54	0.55	-0.66	-0.66		-0.8	-0.02	-0.73	0.25	-0.03	-0.86	-0.83	-0.55	-0.82	-0.98	-0.66	-0.91	-0.16	0.53	0.52	-0.69	-0.1	-0.31	0.9
Accounts Payable	0.14	0.42	0.6	-0.18	0.38	0.14	-0.8		0.19	0.39	0.18	0.0	0.65	0.88	0.07	0.82	0.86	0.21	0.83	0.11	-0.55	-0.55	0.75	0.36	-0.12	-0.56
Cash	0.76	0.38	0.04	0.47	0.46	-0.3	-0.02	0.19		0.29	0.26	0.79	-0.03	0.05	0.25	-0.2	0.13	0.25	0.12	0.77	-0.46	-0.44	-0.25	-0.3	-0.05	-0.11
Non Current Assets Total	0.54	0.79	0.37	-0.41	0.94	0.7	-0.73	0.39	0.29		-0.44	0.41	0.75	0.38	0.82	0.31	0.69	0.89	0.63	0.49	-0.39	-0.43	0.18	-0.35	0.48	-0.82
Non Currrent Assets Other	0.02	-0.3	-0.04	0.59	-0.29	-0.7	0.25	0.18	0.26	-0.44		0.1	-0.34	0.09	-0.58	-0.1	-0.11	-0.57	-0.14	0.05	-0.26	-0.28	-0.08	0.33	-0.77	0.43
Cash And Short Term Investments	0.98	0.65	-0.03	0.55	0.6	-0.06	-0.03	0.0	0.79	0.41	0.1		0.08	0.0	0.42	-0.33	0.16	0.4	0.08	0.99	-0.52	-0.5	-0.25	-0.69	-0.02	-0.17
Net Receivables	0.25	0.72	0.43	-0.51	0.65	0.69	-0.86	0.65	-0.03	0.75	-0.34	0.08		0.65	0.58	0.68	0.83	0.66	0.81	0.21	-0.31	-0.31	0.66	-0.15	0.16	-0.85
Common Stock Shares Outstanding	0.14	0.53	0.28	-0.25	0.35	0.28	-0.83	0.88	0.05	0.38	0.09	0.0	0.65		0.22	0.92	0.89	0.27	0.93	0.12	-0.58	-0.58	0.83	0.23	-0.07	-0.61
Non Current Liabilities Total	0.52	0.75	0.02	-0.5	0.81	0.81	-0.55	0.07	0.25	0.82	-0.58	0.42	0.58	0.22		0.18	0.46	0.96	0.48	0.48	-0.33	-0.33	0.01	-0.56	0.62	-0.8
Other Current Assets	-0.17	0.35	0.31	-0.52	0.2	0.4	-0.82	0.82	-0.2	0.31	-0.1	-0.33	0.68	0.92	0.18		0.81	0.24	0.89	-0.19	-0.33	-0.33	0.88	0.39	0.05	-0.62
Other Stockholder Equity	0.32	0.74	0.53	-0.37	0.65	0.52	-0.98	0.86	0.13	0.69	-0.11	0.16	0.83	0.89	0.46	0.81		0.57	0.92	0.29	-0.62	-0.62	0.73	0.07	0.18	-0.83
Total Liab	0.51	0.78	0.29	-0.55	0.88	0.84	-0.66	0.21	0.25	0.89	-0.57	0.4	0.66	0.27	0.96	0.24	0.57		0.53	0.47	-0.38	-0.38	0.05	-0.45	0.63	-0.89
Property Plant And Equipment Gross	0.25	0.69	0.3	-0.4	0.58	0.5	-0.91	0.83	0.12	0.63	-0.14	0.08	0.81	0.93	0.48	0.89	0.92	0.53		0.22	-0.55	-0.55	0.76	0.05	0.12	-0.79
Total Current Assets	1.0	0.74	0.02	0.47	0.66	0.03	-0.16	0.11	0.77	0.49	0.05	0.99	0.21	0.12	0.48	-0.19	0.29	0.47	0.22		-0.57	-0.56	-0.12	-0.68	0.01	-0.28
Common Stock Total Equity	-0.58	-0.55	-0.26	-0.12	-0.61	-0.13	0.53	-0.55	-0.46	-0.39	-0.26	-0.52	-0.31	-0.58	-0.33	-0.33	-0.62	-0.38	-0.55	-0.57		0.97	-0.32	0.26	-0.16	0.43
Common Stock	-0.57	-0.52	-0.25	-0.12	-0.6	-0.14	0.52	-0.55	-0.44	-0.43	-0.28	-0.5	-0.31	-0.58	-0.33	-0.33	-0.62	-0.38	-0.55	-0.56	0.97		-0.3	0.22	-0.14	0.42
Current Deferred Revenue	-0.1	0.33	0.23	-0.25	0.1	0.23	-0.69	0.75	-0.25	0.18	-0.08	-0.25	0.66	0.83	0.01	0.88	0.73	0.05	0.76	-0.12	-0.32	-0.3		0.2	-0.06	-0.41
Other Liab	-0.68	-0.5	0.35	-0.23	-0.48	-0.26	-0.1	0.36	-0.3	-0.35	0.33	-0.69	-0.15	0.23	-0.56	0.39	0.07	-0.45	0.05	-0.68	0.26	0.22	0.2		-0.27	0.12
Other Assets	0.04	0.23	0.11	-0.59	0.45	0.64	-0.31	-0.12	-0.05	0.48	-0.77	-0.02	0.16	-0.07	0.62	0.05	0.18	0.63	0.12	0.01	-0.16	-0.14	-0.06	-0.27		-0.44
Treasury Stock	-0.32	-0.77	-0.47	0.66	-0.77	-0.83	0.9	-0.56	-0.11	-0.82	0.43	-0.17	-0.85	-0.61	-0.8	-0.62	-0.83	-0.89	-0.79	-0.28	0.43	0.42	-0.41	0.12	-0.44

Click cells to compare fundamentals

Accelerate Diagnostics Account Relationship Matchups

Accelerate Diagnostics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	134.4M	93.4M	83.0M	65.0M	31.4M	48.2M
Other Current Liab	5.1M	4.3M	3.8M	3.2M	3.4M	3.6M
Total Current Liabilities	8.2M	7.0M	6.9M	66.6M	12.0M	12.6M
Total Stockholder Equity	(7.4M)	(62.8M)	(35.1M)	(22.3M)	(19.9M)	(18.9M)
Property Plant And Equipment Net	11.8M	9.3M	7.9M	7.8M	5.1M	2.7M
Net Debt	73.1M	114.2M	71.2M	42.6M	27.1M	28.4M
Retained Earnings	(414.7M)	(493.0M)	(570.7M)	(607.2M)	(668.9M)	(635.4M)
Accounts Payable	2.4M	1.3M	2.0M	4.5M	4.8M	5.0M
Cash	61.0M	35.8M	39.9M	34.9M	12.1M	23.7M
Non Current Assets Total	12.6M	11.4M	9.7M	9.0M	6.9M	5.4M
Non Currrent Assets Other	750K	(5.9M)	1.8M	1.2M	1.8M	1.9M
Cash And Short Term Investments	108.5M	68.3M	63.6M	45.6M	13.2M	12.6M
Net Receivables	3.2M	1.6M	2.3M	2.4M	2.6M	2.8M
Common Stock Shares Outstanding	5.4M	5.5M	5.6M	6.2M	12.5M	13.1M
Liabilities And Stockholders Equity	134.4M	93.4M	83.0M	65.0M	31.4M	48.2M
Non Current Liabilities Total	133.6M	149.3M	111.2M	20.7M	39.2M	23.3M
Other Current Assets	1.2M	1.8M	1.6M	2.0M	5.3M	5.6M
Other Stockholder Equity	407.3M	430.0M	535.6M	585.3M	649.6M	682.0M
Total Liab	141.8M	156.2M	118.1M	87.3M	51.3M	28.6M
Property Plant And Equipment Gross	11.8M	9.3M	7.9M	7.8M	16.1M	16.9M
Total Current Assets	121.9M	82.0M	73.3M	56.0M	24.5M	42.8M
Accumulated Other Comprehensive Income	(58K)	91K	(60K)	(400K)	(612K)	(581.4K)
Common Stock Total Equity	56K	54K	55K	58K	52.2K	49.6K
Common Stock	55K	58K	68K	97K	14K	13.3K
Current Deferred Revenue	271K	376K	451K	547K	1.5M	1.6M
Other Liab	19K	335K	808K	1.5M	1.4M	1.5M
Other Assets	750K	5.3M	1.8M	1.2M	1.0	0.95
Property Plant Equipment	7.9M	6.1M	7.9M	7.8M	8.9M	9.4M
Inventory	8.1M	9.2M	5.1M	5.2M	3.3M	2.7M
Net Tangible Assets	(7.4M)	(62.8M)	(35.1M)	(22.3M)	(20.0M)	(19.0M)
Long Term Debt	130.0M	145.9M	108.0M	16.9M	36.1M	51.1M
Retained Earnings Total Equity	(330.3M)	(414.7M)	(493.0M)	(570.7M)	(513.6M)	(487.9M)
Short Term Investments	47.4M	32.5M	23.7M	10.7M	1.1M	1.0M
Capital Surpluse	432.9M	452.3M	475.1M	580.7M	667.7M	701.1M
Non Current Liabilities Other	3.6M	3.4M	3.2M	874K	1.2M	1.6M
Short Long Term Debt Total	134.1M	150.0M	111.1M	77.5M	39.2M	37.3M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
CRM	Salesforce
MSFT	Microsoft

When determining whether Accelerate Diagnostics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Accelerate Diagnostics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Accelerate Diagnostics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Accelerate Diagnostics Stock:

How To Invest In Accelerate

Details

Is Accelerate Stock a good investment?

Details

What is Accelerate Diagnostics' Net Worth?

Details

Largest Life Sciences Tools & Services Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Accelerate Diagnostics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.

For more information on how to buy Accelerate Stock please use our How to Invest in Accelerate Diagnostics guide.

Note that the Accelerate Diagnostics information on this page should be used as a complementary analysis to other Accelerate Diagnostics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.

Complementary Tools for Accelerate Stock analysis

When running Accelerate Diagnostics' price analysis, check to measure Accelerate Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Accelerate Diagnostics is operating at the current time. Most of Accelerate Diagnostics' value examination focuses on studying past and present price action to predict the probability of Accelerate Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Accelerate Diagnostics' price. Additionally, you may evaluate how the addition of Accelerate Diagnostics to your portfolios can decrease your overall portfolio volatility.

	Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets
	Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments
	Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges
	Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
	Bonds Directory Find actively traded corporate debentures issued by US companies

Is Accelerate Diagnostics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Accelerate Diagnostics. If investors know Accelerate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Accelerate Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(4.94)

Revenue Per Share

0.966

Quarterly Revenue Growth

0.019

Return On Assets

(0.70)

The market value of Accelerate Diagnostics is measured differently than its book value, which is the value of Accelerate that is recorded on the company's balance sheet. Investors also form their own opinion of Accelerate Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Accelerate Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Accelerate Diagnostics' market value can be influenced by many factors that don't directly affect Accelerate Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Accelerate Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Accelerate Diagnostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Accelerate Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Accelerate Current Deferred Revenue vs Other Stockholder Equity Analysis

Current Deferred Revenue vs Other Stockholder Equity

Current Deferred Revenue vs Other Stockholder Equity Correlation Analysis

Correlation Coefficient

Current Deferred Revenue

Other Stockholder Equity

Accelerate Diagnostics fundamental ratios Correlations

Accelerate Diagnostics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Accelerate Diagnostics fundamental ratios Accounts

Also Currently Popular

Complementary Tools for Accelerate Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Total Current Assets	+ 0.99	Cash And Short Term Investments
Cash And Short Term Investments	+ 0.98	Total Assets
Common Stock	+ 0.97	Common Stock Total Equity
Total Liab	+ 0.96	Non Current Liabilities Total
Non Current Assets Total	+ 0.94	Property Plant And Equipment Net

Other Stockholder Equity	- 0.98	Retained Earnings
Property Plant And Equipment Gross	- 0.91	Retained Earnings
Treasury Stock	- 0.89	Total Liab
Net Receivables	- 0.86	Retained Earnings
Treasury Stock	- 0.85	Net Receivables
Treasury Stock	- 0.83	Other Stockholder Equity